CSL Behring Parent Company, CSL Limited, Issues Fourth Corporate Responsibility Report

       CSL Behring Parent Company, CSL Limited, Issues Fourth Corporate
                            Responsibility Report

The report provides a comprehensive account of CSL's economic, social and
environmental performance for 2011/2012.

PR Newswire

KING OF PRUSSIA, Pa., Dec. 3, 2012

KING OF PRUSSIA, Pa., Dec. 3, 2012 /PRNewswire/ --CSL Behring's parent
company, CSL Limited (ASX: CSL), reaffirms the company's commitment to
responsible business practice and sustainable development in its fourth
Corporate Responsibility Report – Our Corporate Responsibility 2012. The
report details CSL's performance across key corporate responsibility priority
areas for the period July 1, 2011 through June 30, 2012.

(Logo: http://photos.prnewswire.com/prnh/20100914/PH63692LOGO )

The priority areas include the Company's research into new and improved
medicines, ensuring the safety and quality of its broad portfolio of
therapies, providing a positive and healthy work environment for employees,
behaving responsibly in the global marketplace, providing charitable support
for communities in need around the world and minimizing the environmental
impacts of its operations. Highlights of CSL's performance in these areas

  oRecognition of sustainable development and leadership by the FTSE4Good
    Index Series in 2011 and 2012 (FTSE4Good Index objectively measures the
    performance of companies that meet globally recognized corporate
    responsibility standards);
  oResearch and Development investment of A$355 million dollars, with more
    than 30 clinical studies in operation across our portfolio of specialty
    and hemophilia products, breakthrough medicines and immunoglobulin-based
  oEconomic contribution direct to local economies of more than A$4.2
    billion, including global community (stakeholders and local communities)
    investment of A$35.4 million;
  o2% growth in the total workforce with year-on-year reductions in recorded
    rates of lost time injury frequency and medical treatment injury
    frequency, including an 8% and 26% reduction from 2011, respectively;
  o4% reduction in energy and water consumption and greenhouse gas emissions
    per unit of plasma production.

"CSL's reputation as one of the most innovative biopharmaceutical companies in
the world and our continued growth are underscored by our commitment to
conducting our business responsibly, and actively contributing to the
well-being of our communities," said Dr. Brian McNamee, CEO and Managing
Director of CSL Limited. "Our Corporate Responsibility Report for 2012
demonstrates this ongoing commitment."

About CSL Limited
Headquartered in Melbourne, Australia, CSL Limited (AUX: CSL) is a global
biopharmaceutical company that develops, manufactures and markets biotherapies
to prevent and treat rare and serious human diseases. CSL owns major
facilities in Australia, Germany, Switzerland and the US, and employs over
11,000 people in more than 25 countries. For more information visit

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed
to saving lives and improving the quality of life for people with rare and
serious diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders
including hemophilia and von Willebrand disease, primary immune deficiencies,
hereditary angioedema and inherited respiratory disease. The company's
products are also used in cardiac surgery, organ transplantation, burn
treatment and to prevent hemolytic diseases in the newborn. For more
information visit http://www.cslbehring.com/. CSL Behring operates one of the
world's largest plasma collection networks, CSL Plasma.

View Our Corporate Responsibility 2012 at

Chris Florentz
Manager, Corporate Communications
CSL Behring
King of Prussia,
+1 610 878 4316


Website: http://www.cslbehring.com
Press spacebar to pause and continue. Press esc to stop.